Avidity Partners Management LP: PERSPECTIVE THERAPEUTICS (CATX): Quarterly 13F Position History
As of Q1 2026, Avidity Partners Management LP reported 6,049,999 shares of PERSPECTIVE THERAPEUTICS (CATX), worth $23.6M and representing 5.3% of its 13F equity book. Quarter-over-quarter share count change: + 2,839,266 (+88.4%) . The position first appeared in Q2 2024 and has been disclosed across 8 13F-HR filings in Pactolio's tracked window.
- 6,049,999Shares Held (Latest Filing)
- $23.6MReported Market Value (Latest Filing)
- 5.3%Portfolio Weight (% of 13F Equity Book)
- +2,839,266Quarter-over-Quarter Share Change
- +$14.8MQuarter-over-Quarter Value Change
- 6,049,999Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 8 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 6,049,999 | +2,839,266 | +88.4% | $23.6M | 5.3% | $3.9 |
| Q4 2025 | 3,210,733 | +216,700 | +7.2% | $8.8M | 2.5% | $2.8 |
| Q3 2025 | 2,994,033 | +1,135,437 | +61.1% | $10.3M | 2.3% | $3.4 |
| Q2 2025 | 1,858,596 | 338,674 | -15.4% | $6.4M | 1.3% | $3.4 |
| Q1 2025 | 2,197,270 | 497,330 | -18.5% | $4.7M | 1.0% | $2.1 |
| Q4 2024 | 2,694,600 | 749,402 | -21.8% | $8.6M | 0.9% | $3.2 |
| Q3 2024 | 3,444,002 | +406,334 | +13.4% | $46.0M | 2.3% | $13.3 |
| Q2 2024 | 3,037,668 | — | — | $30.3M | 1.3% | $10.0 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avidity Partners Management LP first disclose a CATX position in 13F-HR filings?
Avidity Partners Management LP first reported PERSPECTIVE THERAPEUTICS (CATX) on its 13F-HR filing for the period ending 2024-06-30 (Q2 2024). The position has appeared on 8 reported quarters within Pactolio's tracked window.
What was Avidity Partners Management LP's most recent quarter-over-quarter share-count change in CATX?
Between Q4 2025 and Q1 2026, Avidity Partners Management LP added 2,839,266 shares of CATX (+88.4%), bringing the total reported position to 6,049,999 shares at a market value of $23.6M.
Does the implied price-per-share represent Avidity Partners Management LP's cost basis in CATX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.